Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 9/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 9/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17446878 | 0.89 | NOTUM (0.62) | NOTUMCNR2XIAPBIRC2HSD17B3 | |
| SCHEMBL1830230 | 0.82 | XIAP (0.43) | XIAPBIRC2HSD17B3MYCNR4A1 | |
| SCHEMBL13732568 | 0.79 | XIAP (0.57) | XIAPBIRC2HSD17B3CASP2LMNA | |
| SCHEMBL13416586 | 0.77 | NOTUM (0.44) | NOTUMLMNAALDH1A1 | |
| SCHEMBL23671532 | 0.77 | PIK3CA (0.42) | NOTUMXIAPBIRC2HSD17B3ALDH1A1 | |
| SCHEMBL1829099 | 0.77 | XIAP (0.36) | XIAPBIRC2HSD17B3MYCNR4A1 | |
| SCHEMBL1829103 | 0.77 | XIAP (0.36) | XIAPBIRC2HSD17B3MYCNR4A1 | |
| SCHEMBL1829105 | 0.77 | XIAP (0.36) | XIAPBIRC2HSD17B3MYCNR4A1 | |
| SCHEMBL6527995 | 0.76 | NOTUM (0.62) | NOTUMCNR2HSD17B3ALDH1A1 | |
| SCHEMBL7984446 | 0.76 | NOTUM (0.77) | NOTUMCNR2BIRC2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987473-B2 | Ring-fused compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20140005221-A1 | RING-FUSED COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005221-A1 | RING-FUSED COMPOUND | URB2, RCOR1, RCC2 | NOTUM 2742/4885CNR2 1285/4885XIAP 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.